Company
Headquarters: Calgary, AB, Canada
CEO: Ms. Iris Bincovich
$51.6 Million
USD as of July 1, 2025
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in Israel. It engages in the research and development of Covid-19 treatment by using CBD loaded exosomes; and CBD loaded liposomes. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. In addition, it develops SHIR premium CBD facial serum products. The company was incorporated in 2018 and is based in Calgary, Canada.
InnoCan Pharma Corp has the following listings and related stock indices.
Stock: OTC: INNPF
Stock: CSE: INNO
Stock: FSX: IP4